Domp

Pharmaceuticals, Milano, Lombardia, Italy, 501-1000 Employees

Who is DOMP

Dompe farmaceutici is an international biopharmaceutical company involved in all activities of the pharmaceutical value chain, from research to development, production and marketing. As a...

Get Full Access

Headquarters: Milano, Lombardia, Italy
Employees: 501-1000
Revenue: $250 Million to $500 Million

Industry: Pharmaceuticals

SIC Code: 5122 | NAICS Code: 449122 | Show More

Does something look wrong? Fix it. | View contact records from DOMP

Domp Org Chart and Mapping

Employees

Sarah Wilting

Associate Scientific Director, Ophthalmics

Email
Phone

Sheila Folayan

U.S. Compliance Officer (Head of U.S. Compliance)

Email
Phone

Thayer Darling

Associate Director, Global Publications

Email
Phone

Jennifer Cross

Senior Director, Field Marketing

Email
Phone

Heather Trenteseaux

Senior Key Account Manager- Rare Disease

Email
Phone

Marco Tenconi

Director, Controlling

Email
Phone

See Full Org Chart

View Email Formats for Domp

You are signed out

Join Now

Free credits every month

Frequently Asked Questions Regarding Domp

Answer: Domp's headquarters are located at Milano, Lombardia, Italy,

Answer: Dompe farmaceutici is an international biopharmaceutical company involved in all activities of the pharmaceutical value chain, from research to development, production and marketing. As a long-established family company, we blend the stability that comes from our 130-year heritage with the agility and dynamism of a start-up. We can turn transformative breakthroughs into treatments because we have the right qualities and capabilities to deliver new drugs. Our 160,000 square meter R&D and production site in LAquila, Italy, is the heart of Dompe. Here, we conduct vital research, and produce and distribute our primary care and biotech products. Primary Care includes a broad spectrum of over-the-counter treatment solutions, prescription medications, supplements and medical devices. Our Biotech focuses on the development of treatments for rare diseases. The main therapeutic areas include pain relief, inflammation, ophthalmology, diabetes care, nutrition and oncology. In the pursuit of improving human health, our R&D strives to break through in unconventional places. This is what led us to Nerve Growth Factor (NGF), a Nobel Prize-winning discovery made in 1986. We leveraged 50 years of research to transform this discovery into a breakthrough treatment. Our human recombinant NGF, cenegermin, is the first treatment for a rare degenerative eye disease, neurotrophic keratitis. That deep appreciation of science keeps us committed to investigating neurotrophins. Our relentless pursuit in identifying new treatments for diseases allowed us to harness the potential of bioinformatics to accelerate the drug discovery process. The result is Exscalate, a structure-based virtual screening platform developed in-house and currently one of the most powerful supercomputing and artificial intelligence platforms for drug testing. We are focused on the road ahead. Our hunger to deliver what patients need from science keeps us focused on what matters. We embrace the challenge in science.